A First-in-Human Single and Multiple Ascending Dose Study of MT-251

Part of paid clinical trials in San Diego, California.

Sponsor
Mirador Therapeutics, Inc.
Study ID
NCT07423299
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
19 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • MT-251 — DRUG
    MT-251

Study Details

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants

Key Dates

Start date
Jan 23, 2026
Status verified
Jan 2026
Primary completion
Mar 8, 2027
Completion
Mar 8, 2027

Study Design

Enrollment
70 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1- Single Ascending Dose
    To assess the safety and tolerability of single intravenous/subcutaneous dose of MT-251.
  • Experimental: Part 2- Multiple Ascending Dose
    To assess the safety and tolerability of multiple intravenous/subcutaneous doses of MT-251.

Primary Outcome Measure

Number of Subjects with non-SAEs and SAES [ Time Frame: Up to 14 days post dose. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mirador Clinical DepartmentSan DiegoCalifornia92121
Toll-Free Number
[email protected]
844-206-4980

Find similar trials in San Diego, CA

By research site
Mirador Clinical Department· San Diego, CA

Related Studies